Nonprescription Drugs USA

Nonprescription Drugs USA

Base year: 2017
Data Released March 2018
Report Published June 2018
Regional Coverage: United States

A comprehensive analysis of the U.S. nonprescription drugs industry, focusing on key trends, developments, challenges, business opportunities, and new product activity, and offers insights and information on the following:

  • Industry trends
  • Market size and performance
  • Brand sales and share
  • Company sales and share
  • New product activity
  • Retail distribution
  • Regulatory developments
  • Rx-to-OTC switch forecasts
  • Five-year historical sales
  • Five-year sales forecasts

Features user-friendly database that is fully searchable and exportable that contains sales data, growth, share, and forecasts for hundreds of brands and companies across more than 20 categories. Through its alliance with IRI, Kline now includes as part this report analysis of IRI MULO data for year ending 2017.

Report Contents


Executive Summary
An executive briefing covering developments in 2017, the impact of key trends and issues in the nonprescription drug business, and their future implications for industry participants. Includes analysis of retail distribution, private-label activity, and five-year forecasts through 2023.

Pertinent information plus insightful analysis of 22 major categories, including key trends and developments; manufacturers’ sales for 2016 and 2017, sales and market shares for leading brands, new product activity, sales by retail channel, private-label sales, marketing activity, and outlook to 2022. The product categories covered are shown in Table 1.

Major Companies
Profiles for 11 major companies, including company activities; sales by product category and major brands in 2016 and 2017; recent developments including acquisitions, divestitures, and new products; corporate overview; and an outlook to 2022. The major companies covered are shown in Table 2.


Table 1: Product Categories Profiled
Digestive Products Topical Products
• Antacids and antigas
• Antidiarrheal preparations
• Antinausea preparations
• Laxatives
• Anti-itch products
• Corn, callus, and wart removers
• Diaper rash products
• Eye care products
• First aid products
• Fungicidal preparations
• Oral care products
• Topical analgesics
Internal Analgesics Upper Respiratory Products
• General pain relievers
• Other internal analgesics
• Allergy and asthma relief products
• Cold and sinus medications
• Cough drops and sore throat remedies
• Cough syrups
• Nasal and topical decongestants
Nutritional Products Other Products
• Herbal products
• Vitamins and minerals
• Sleeping aids
Table 2: Major Companies Profiled
Bayer Group
Carlyle Group
Church & Dwight
Johnson & Johnson
Perrigo Company
Prestige Brands
Procter & Gamble
Reckitt Benckiser

Scope & Benefits

Nonprescription Drugs USA is an extensive industry resource used widely by marketing executives
and other industry participants for competitive analysis, market investigation for new products,
acquisition screening, and business planning. This report focuses solely on nonprescription drugs sold
through domestic consumer outlets, including those marketed via drug stores, food stores, and mass
merchandisers, in addition to nontraditional outlets such as health food stores, convenience stores,
warehouse clubs, dollar stores, mail order, and online. Market data refer exclusively to sales through
these outlets. Direct and mail order sales are included, but sales to institutions such as hospitals and
nursing homes and exports are excluded.

For more than 50 years, the study has proven to be the most authoritative and comprehensive annual
source of information on the nonprescription drug industry. It contains industry trends and market size
data for 22 product categories. In addition, market share and brand sales information are reported.
The study profiles 11 leading major companies. Included in the report is an analysis of regulatory
developments, retail distribution, and private-label products.

Subscribers to Nonprescription Drugs USA are afforded the following benefits:

  • Access to the most comprehensive and authoritative independent source of information and insights on the U.S. nonprescription drugs industry
  • Access to accurate sales data through all outlets based on primary research with knowledgeable
    industry participants
  • One day of consultation time to be used within 6 months of report publication
  • A tool to learn about categories or brands that could be potential new entry/acquisition opportunities
  • Access to periodic podcasts on timely topics from Kline’s industry experts
  • A source of valuable competitive information and intelligence
  • Understand industry trends that may impact your categories and/or brands
  • Learn about expected future Rx-to-OTC switches and their expected impacts on existing OTC categories
  • Depth of knowledge with historical sales and trend information, as well as five-year sales forecasts
  • Assessment of new product activity in each category
  • Access to Kline’s searchable, exportable database with rolling six years of sales data on hundreds of brands and companies across 22 categories

Price Anchor


Posted in .